Article (Scientific journals)
Calcitonin for Prevention and Treatment of Osteoporosis
Reginster, Jean-Yves
1993In American Journal of Medicine, 95 (5A), p. 44S-47
Peer Reviewed verified by ORBi
 

Files


Full Text
Calcitonin for Prevention and Treatment of Osteoporosis.pdf
Publisher postprint (1.94 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] There appears to be a consensus that 100 IU/day of nasally administered salmon calcitonin may prevent trabecular bone loss during the first year of the menopause. Strong evidence exists that half that dose may also be sufficient to prevent trabecular bone loss and that higher doses (> or = 200 IU/day) induce a significant increase in spinal bone mineral content. Calcium supplements should be systemically administered when calcitonin is given, particularly at high doses. Rectal calcitonin seems also to be an efficient alternative in prevention of trabecular bone loss. Further studies are required to evaluate the effect of calcitonin in prevention of cortical bone loss. In established osteoporosis calcitonin may prevent further bone loss at trabecular and cortical sites. A similar benefit is obtained following parenteral or nasal administration of the drug. Long-term administration of nasal salmon calcitonin induces a significant dose-dependent gain of bone at the lumbar spine, whereas discontinuous therapy with a ratio of 1:2 or 2:3 between the treatment and nontreatment periods is the best regimen for cortical bone. Epidemiological, retrospective, and prospective studies provide a convergent network of evidence that calcitonin administration in osteoporosis contributes to reduce significantly the frequency of subsequent fractures, both in the spine and in the hip. Finally, in established osteoporosis, nasal calcitonin possesses a potent analgesic effect, reduces the duration of bed confinement, and decreases the number of concomitant analgesic medications. The well-demonstrated effects of nasal calcitonin permit it to be considered as a highly rational solution for the prevention and the treatment of postmenopausal osteoporosis.
Disciplines :
Rheumatology
Author, co-author :
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Calcitonin for Prevention and Treatment of Osteoporosis
Publication date :
30 November 1993
Journal title :
American Journal of Medicine
ISSN :
0002-9343
eISSN :
1555-7162
Publisher :
Excerpta Medica, United States - New York
Volume :
95
Issue :
5A
Pages :
44S-47S
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 12 June 2012

Statistics


Number of views
50 (1 by ULiège)
Number of downloads
1 (0 by ULiège)

Scopus citations®
 
71
Scopus citations®
without self-citations
65
OpenCitations
 
52

Bibliography


Similar publications



Contact ORBi